Search Bar & Filters
Found 7 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.
Actively Recruiting
Researchers are studying younger breast cancer survivors who experience elevated depressive symptoms to compare digital mindfulness meditation programs. This phase III clinical trial evaluates two digital methods a live instructor-led program over Zoom and a self-paced app-based program. The study aims to find which digital approach best improves mental health and well-being after completing primary cancer treatment. Participants are randomly assigned to one of three groups a live online mindfulness group meeting weekly for six weeks via Zoom a self-paced app-based mindfulness program with lessons and exercises unlocked sequentially or a meditation-only control group using guided audio meditations. All participants will have access to the mindfulness meditation app throughout the study, including six months of follow-up. Devices and internet access are provided to those who need them. During the study, participants will attend group sessions or use the app according to their assigned group and complete daily mindfulness practice. Researchers will track engagement and measure depressive symptoms at two weeks, three to six months, and six months after the intervention. They will also assess fatigue and explore factors influencing treatment effects and cost-effectiveness. The total study duration spans the six-week intervention plus six months of follow-up.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
This research aims to collect and analyze long-term data on the use of Stereotactic Radiosurgery SRS and Stereotactic Body Radiation Therapy SBRT in treating patients with life-threatening tumors and other medical conditions. The study is an international, multi-year observational registry designed to understand how these treatments are used and their outcomes in everyday clinical practice. It continues the work of a prior study focused on CyberKnife treatment and is sponsored by The Radiosurgery Society. Participants in this study include patients with various conditions considered treatable by SRS or SBRT. The study captures information such as patient characteristics, disease details, treatment plans, and outcomes. This data collection allows participating sites to track treatment effectiveness and share their experiences. The registry is maintained by Vision Tree, Inc., which ensures data security and compliance with privacy regulations. Both prospective and some retrospective patient data are included. During the study, participants treatment outcomes are monitored over time, including overall survival for up to five years and local or distant recurrence within one to five years. The registry allows detailed recording of outcomes specific to each condition treated. Patients provide consent to participate, and their data contributes to improving understanding of these advanced radiation therapies. The total duration of participation varies as the study is ongoing and collects long-term results.
Actively Recruiting
Researchers are studying how well serum tumor marker directed disease monitoring works compared to the usual monitoring approach for patients with hormone receptor positive, HER2 negative metastatic breast cancer. This trial aims to see if monitoring patients with specific blood markers to decide when to perform scans leads to similar overall survival as the standard care. The study also explores healthcare costs and patient-reported anxiety and quality of life between these monitoring methods. Participants are randomly assigned to one of two groups. One group receives usual care with imaging at least every 12 weeks and tumor marker tests as decided by their doctor. The other group undergoes regular serum tumor marker tests every 4 to 8 weeks, and imaging is only done if these markers rise. Both groups continue their assigned monitoring until disease progression or up to 312 weeks. During the study, participants complete questionnaires about anxiety and quality of life. Researchers collect data on overall survival, healthcare costs, and patient experiences over various timeframes, including up to 312 weeks for survival and 102 weeks for patient-reported outcomes. Monitoring is consistent at facilities accessible to the study team, and participants are followed closely while on their assigned monitoring approach throughout the study period.
Actively Recruiting
Researchers are comparing two treatments for patients with 5 or more brain metastases stereotactic radiosurgery SRS and hippocampal-avoidant whole brain radiotherapy HA-WBRT combined with the drug memantine. This study aims to find out if SRS is better, the same, or worse than the usual treatment approach, which is whole brain radiation therapy alone. The study will assess how these treatments affect cancer control, overall survival, memory, quality of life, and cancer-related symptoms. Participants will be randomly assigned to receive either SRS, which delivers a high dose of radiation to specific small areas in the brain in a single session, or HA-WBRT plus memantine. HA-WBRT involves radiation to the whole brain while avoiding the hippocampus area to protect memory, given in 10 radiation fractions totaling 30Gy. Memantine is given starting at 5 mg and increased weekly to a target dose of 20 mg daily in divided doses. Treatment is provided as an outpatient procedure. During the study, participants will undergo regular assessments including MRI scans, neurocognitive testing, quality of life questionnaires, and blood tests to measure biomarkers. Researchers will monitor survival, brain cancer control, cognitive function, side effects, and treatment costs over 4.5 years. The study also includes collecting imaging and blood samples to understand treatment effects and brain changes. Participants are expected to be available for treatment, follow-up, and completing questionnaires throughout the study period.
Actively Recruiting
Researchers are evaluating whether adjusting the timing of doses for the prostate cancer drug lutetium 177 Lu PSMA RLT can improve quality of life without shortening lifespan in patients with hormone-resistant prostate cancer that has spread locally or to distant sites. This phase III trial compares the standard fixed 6-week dosing schedule to an adaptive schedule where treatment intervals may be lengthened based on disease activity. The study focuses on men with metastatic castration-resistant prostate carcinoma who have tumors expressing the PSMA protein. Participants initially receive two cycles of lutetium 177 Lu PSMA RLT intravenously, repeated every 6 weeks. Those showing a significant PSA decline then enter randomization one group continues the standard dosing every 6 weeks for up to four additional cycles, while the other group undergoes PSA monitoring every three weeks and receives treatment only when specific PSA or clinical progression criteria are met, allowing for adaptive dosing. Throughout the trial, patients undergo blood tests, CT scans, bone scans, and PSMA PET imaging at screening, with MRI scans for those with brain metastases or clinical indications. During the study, participants are monitored regularly with blood samples and imaging to assess disease progression and treatment effects. Quality of life is measured using standardized questionnaires over 30 months, and survival is tracked for up to five years. Follow-up visits occur every 12 weeks after treatment completion until disease progression, then every six months for up to five years. Researchers also evaluate treatment toxicity, pain severity, PSA response, and other health outcomes to compare the adaptive and standard dosing approaches.